Palatin Technologies (LTS:0KF3) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KF3 Palatin Technologies Inc LTS:0KF3
45 GF Score
Price $11.14
GF Value $51.03
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Palatin Technologies SpecialCharges?

Special Charges only applies to banks.

LTS:0KF3
45GF Score
Palatin Technologies Inc LTS:0KF3
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Palatin Technologies (LTS:0KF3) Overvalued in 2026?

Based on GuruFocus' analysis, Palatin Technologies stock appears to be undervalued. The current stock price of $11.14 is trading 78.2% below its estimated GF Value™ of $51.03. GuruFocus considers Palatin Technologies to be Possible Value Trap.

Key valuation signals for LTS:0KF3:

  • SpecialCharges:
  • GF Value™: $51.03 vs. price of $11.14 (78.2% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the LTS:0KF3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Palatin Technologies Business Description

Other Exchanges PTN:USA
Address 103 Carnegie Center Drive, Suite 300, Princeton, NJ, USA, 08852
Palatin Technologies Inc. is a biopharmaceutical company that develops receptor-specific peptide therapeutics based on molecules that modulate the melanocortin receptor system. Its pipeline targets diseases with unmet medical needs, with programs focused on melanocortin-1 receptor (MC1R) agonists for inflammatory and dermatologic conditions and melanocortin-4 receptor (MC4R) agonists for metabolic and other indications. The company's most commercially advanced product is bremelanotide, an MC4R agonist marketed as Vyleesi for hypoactive sexual desire disorder in premenopausal women, which was approved by the FDA in 2019 and is licensed to a commercial partner in the United States. Palatin operates in a single business segment, life sciences, and generates revenue primarily through licensing fees, milestone payments, royalties, and collaboration agreements rather than direct product sales. The company is headquartered in Cranbury, New Jersey, and its activities are concentrated in the United States.
45GF Score

Get the complete analysis for LTS:0KF3

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.14
Price
$51.03
GF Value